Get the Stockscreener App
2.85
3.26%
0.09
Pre-market:
2.85
Immunitybio Inc stock is traded at $2.85, with a volume of 10.77M.
It is up +3.26% in the last 24 hours and up +17.28% over the past month.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
See More
Previous Close:
$2.76
Open:
$2.81
24h Volume:
10.77M
Relative Volume:
1.26
Market Cap:
$2.69B
Revenue:
$1.31M
Net Income/Loss:
$-597.65M
P/E Ratio:
-2.9381
EPS:
-0.97
Net Cash Flow:
$-425.62M
1W Performance:
+10.04%
1M Performance:
+17.28%
6M Performance:
+1.42%
1Y Performance:
-16.67%
1-Day Range:
$2.79
$2.97
1-Week Range:
$2.54
$2.97
52-Week Range:
$1.83
$7.48
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
2.85 | 2.61B | 1.31M | -597.65M | -425.62M | -0.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.11 | 99.26B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
598.71 | 62.06B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.17 | 59.21B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
731.77 | 44.94B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
342.89 | 36.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-06-25 | Initiated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | BTIG Research | Buy |
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
Immunitybio Inc Stock (IBRX) Latest News
ImmunityBio Inc. (IBRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Biotech Breakouts: 3 Stocks With Massive Upside Potential - Investing.com
Biotech Breakouts: 3 Stocks With Massive Upside Potential - MarketBeat
Insider Sell: Is ImmunityBio Inc stock a smart retirement pick2025 Biggest Moves & Real-Time Market Sentiment Reports - خودرو بانک
ImmunityBio Stock Breaks Out Of Long Slump, Tests $3 Zone: Ex-UBS Analyst Flags ‘Huge’ Bullish Signals - Stocktwits
ETF Watch: Is ImmunityBio Inc. a speculative investmentQuarterly Trade Report & Technical Confirmation Trade Alerts - خودرو بانک
Gainers Report: Is ImmunityBio Inc. forming a double bottomMarket Sentiment Summary & Technical Pattern Based Signals - khodrobank.com
Market Leaders: Will ImmunityBio Inc stock benefit from M AJuly 2025 Closing Moves & Daily Oversold Stock Bounce Ideas - khodrobank.com
ImmunityBio's (IBRX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Is ImmunityBio Inc. gaining market shareWeekly Trend Report & Free Weekly Chart Analysis and Trade Guides - khodrobank.com
Recap Report: Is CDTG stock technically oversoldQuarterly Growth Report & Safe Entry Zone Identification - خودرو بانک
Tech Rally: Does ImmunityBio Inc have a sustainable dividendTake Profit & Consistent Income Trade Ideas - khodrobank.com
Aug Chart Watch: Is ImmunityBio Inc a cyclical or defensive stockJuly 2025 Weekly Recap & Risk Managed Investment Strategies - khodrobank.com
ImmunityBio ($IBRX) Is Paying a $10.5M Settlement to Investors — Here’s How to Get Your Share - TradingView
RSI Check: Will ImmunityBio Inc benefit from rate cutsPortfolio Risk Report & Precise Swing Trade Entry Alerts - خودرو بانک
H.C. Wainwright Reiterates Buy Rating on ImmunityBio, Keeps PT at $8 - Yahoo Finance
ImmunityBio (NASDAQ:IBRX) Trading 7.3% HigherHere's Why - MarketBeat
Why ImmunityBio, Inc. (IBRX) Surged On Thursday - MSN
ImmunityBio's (IBRX) Buy Rating Reiterated at D. Boral Capital - MarketBeat
Why ImmunityBio Inc. stock remains a top recommendationJuly 2025 Gainers & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
ImmunityBio: Still Too Early To Judge Anktiva, Although Clock Is Ticking (NASDAQ:IBRX) - Seeking Alpha
Breakthrough Findings from Phase 2 QUILT-3.055 Study in NSCLCImmunityBio, Inc. - Oncodaily
H.C. Wainwright reiterates Buy rating on ImmunityBio stock, citing promising lung cancer data - Investing.com India
H.C. Wainwright Maintains ImmunityBio(IBRX.US) With Buy Rating, Maintains Target Price $8 - 富途牛牛
ImmunityBio’s Innovative Phase 2 Lymphoma Study: A Potential Game-Changer? - MSN
Sentiment Review: Is ImmunityBio Inc. a cyclical or defensive stock2025 Momentum Check & AI Forecasted Entry/Exit Points - Lancaster City Council
ImmunityBio Stock Rebounds: Bright Outlook Ahead? - StocksToTrade
ImmunityBio’s Stock Surge: Health Revolution or Hype? - timothysykes.com
ImmunityBio’s Surprising Performance: What Lies Ahead? - StocksToTrade
Decliners Report: Is ImmunityBio Inc. gaining market shareMarket Sentiment Summary & Fast Moving Trade Plans - Lancaster City Council
Risk Hedge: Does ImmunityBio Inc. have a sustainable dividendJuly 2025 Volume & Long Hold Capital Preservation Tips - Lancaster City Council
ImmunityBio’s ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy - BioSpace
ImmunityBio Inc. Shows Early Signs of Technical StrengthQuarterly Performance Summary & Technical Pattern Alert System - beatles.ru
Investors Can Still File Late Claims in ImmunityBio Settlement — Here’s How to Get Your Share - TradingView
Is ImmunityBio Inc. stock technically oversoldM&A Rumor & Weekly Top Performers Watchlists - beatles.ru
ImmunityBio’s Anktiva: A Promising Treatment for Long COVID? - TipRanks
Real time scanner hits for ImmunityBio Inc. explainedWeekly Market Outlook & AI Powered Trade Plan Recommendations - Newser
What momentum shifts mean for ImmunityBio Inc.Analyst Downgrade & Consistent Profit Trade Alerts - Newser
A Closer Look at ImmunityBio (IBRX) Valuation Following Promising Early Results in Glioblastoma Study - Yahoo Finance
Rafferty Asset Management LLC Lowers Stock Holdings in ImmunityBio, Inc. $IBRX - MarketBeat
Is ImmunityBio Inc. a speculative investment2025 Key Highlights & Free Fast Gain Swing Trade Alerts - 강소기업뉴스
Is ImmunityBio Inc. reversing from oversold territoryJuly 2025 Reactions & Technical Entry and Exit Alerts - Newser
ImmunityBio Inc. stock volume spike explainedJuly 2025 Action & Momentum Based Trading Ideas - Newser
How to build a custom watchlist for ImmunityBio Inc.Gap Down & Weekly High Return Forecasts - Newser
What’s next for ImmunityBio Inc. stock price2025 Biggest Moves & Daily Stock Trend Watchlist - Newser
Advanced analytics toolkit walkthrough for ImmunityBio Inc.Weekly Investment Recap & Weekly Breakout Stock Alerts - Newser
Applying chart zones and confluence areas to ImmunityBio Inc.Quarterly Portfolio Report & Expert Curated Trade Setups - Newser
ImmunityBio (IBRX) Reports 60% Revenue Growth as ANKTIVA Adoption Accelerates - MSN
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.25%
0.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):